Lung 3H-thymidine incorporation in monocrotaline (MCT)-treated rats - Role of platelet-activating factor (PAF)

S. Ono, T. Tanita, Y. Ashino, M. Noda, S. Tabata, Y. Hoshikawa, S. Ueda, T. Nishimura, S. Fujimura

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Monocrotaline (MCT) causes chronic pulmonary hypertension associated with pulmonary vascular thickening in rats. Since components of the pulmonary vascular thickening are reflected in increased DNA synthesis in medial smooth muscle cells, and since platelet-activating factor (PAF) has been reported to contribute to the pulmonary hypertension induced by MCT, we examined the effect of WEB 2170, a specific PAF receptor blocker, on MCT induced pulmonary vascular thickening and in vitro 3H-thymidine incorporation into lung tissue, as an index of stimulation of cell proliferation. In MCT-treated rats, pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular thickening developed at 3 weeks after injection. Also, in MCT-treated rat lung tissue, there was a significant increase in the in vitro 3H-thymidine incorporation rate. In WEB 2170-treated MCT rats, these changes were significantly less severe than those observed in rats receiving MCT alone. We conclude that PAF plays a role in the inflammatory process that contributes to the development of pulmonary hypertension and vascular remodeling associated with increased lung cell proliferation in MCT-treated rats.

Original languageEnglish
Pages (from-to)441-445
Number of pages5
JournalRespiratory Investigation
Issue number5
Publication statusPublished - 1994


  • H-thymidine incorporation
  • monocrotaline
  • PAF-antagonist
  • platelet-activating factor (PAF)


Dive into the research topics of 'Lung 3H-thymidine incorporation in monocrotaline (MCT)-treated rats - Role of platelet-activating factor (PAF)'. Together they form a unique fingerprint.

Cite this